{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:23:15Z","timestamp":1785810195147,"version":"3.56.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11523-025-01185-x","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:59:26Z","timestamp":1762919966000},"page":"955-965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Weight-Based Pembrolizumab Dosing at 4 mg\/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis"],"prefix":"10.1007","volume":"20","author":[{"given":"Mallika","family":"Lala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Calles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Freshwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy S.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"1185_CR1","unstructured":"KEYTRUDA\u00ae (pembrolizumab) injection, for intravenous use. In: 01\/2025, editor. Rahway: Merck & Co., Inc.; 2025."},{"key":"1185_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0242-5","volume":"5","author":"T Freshwater","year":"2017","unstructured":"Freshwater T, Kondic A, Ahamadi M, et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer. 2017;5:43.","journal-title":"J Immunother Cancer"},{"key":"1185_CR3","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.","journal-title":"N Engl J Med"},{"key":"1185_CR4","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109\u201317.","journal-title":"Lancet"},{"key":"1185_CR5","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1634\/theoncologist.2017-0167","volume":"22","author":"JJMA Hendrikx","year":"2017","unstructured":"Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017;22:1212\u201321.","journal-title":"Oncologist"},{"key":"1185_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","volume":"131","author":"M Lala","year":"2020","unstructured":"Lala M, Li TR, de Alwis DP, et al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer. 2020;131:68\u201375.","journal-title":"Eur J Cancer"},{"key":"1185_CR7","unstructured":"US Food and Drug Administration. FDA approves new dosing regimen for pembrolizumab. In. Bethesda: US Food & Drug Administration; 2022."},{"key":"1185_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0309778","volume":"19","author":"G Cohen","year":"2024","unstructured":"Cohen G, Rapoport B, Chan SW, et al. Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): results from cohort B of an open-label, phase 1 study. PLoS ONE. 2024;19:e0309778.","journal-title":"PLoS ONE"},{"key":"1185_CR9","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1182\/blood-2023-186800","volume":"142","author":"AB McDonald","year":"2023","unstructured":"McDonald AB, Verburgh E, Gotti M, et al. Keynote-B68: updated efficacy and safety of pembrolizumab every six weeks in relapsed\/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma. Blood. 2023;142:4442.","journal-title":"Blood"},{"key":"1185_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejca.2020.07.014","volume":"138","author":"MHM Diekstra","year":"2020","unstructured":"Diekstra MHM, Malmberg R, Sleijfer S, van Leeuwen RWF. Letter to the editor: Comments on \u2018A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.\u2019 Eur J Cancer. 2020;138:54\u20136.","journal-title":"Eur J Cancer"},{"key":"1185_CR11","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1001\/jamaoncol.2020.2493","volume":"6","author":"DA Goldstein","year":"2020","unstructured":"Goldstein DA, Ratain MJ, Saltz LB. Weight-based dosing of pembrolizumab every 6 weeks in the time of COVID-19. JAMA Oncol. 2020;6:1694\u20135.","journal-title":"JAMA Oncol"},{"key":"1185_CR12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/oncolo\/oyad182","volume":"28","author":"M Dub\u00e9-Pelletier","year":"2023","unstructured":"Dub\u00e9-Pelletier M, Labb\u00e9 C, C\u00f4t\u00e9 J, Pelletier-St-Pierre AA. Pembrolizumab every 6 weeks versus every 3 weeks in advanced non-small cell lung cancer. Oncologist. 2023;28:969\u201377.","journal-title":"Oncologist"},{"key":"1185_CR13","unstructured":"US Food and Drug Administration. Guidances. Drugs. In. Silver Spring: US Food & Drug Administration; 2025."},{"key":"1185_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/psp4.12140","volume":"6","author":"MS Chatterjee","year":"2017","unstructured":"Chatterjee MS, Elassaiss-Schaap J, Lindauer A, et al. Population pharmacokinetic\/pharmacodynamic modeling of tumor size dynamics in pembrolizumab-treated advanced melanoma. CPT Pharmacometr Syst Pharmacol. 2017;6:29\u201339.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"1185_CR15","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","volume":"24","author":"DC Turner","year":"2018","unstructured":"Turner DC, Kondic AG, Anderson KM, et al. Pembrolizumab exposure\u2013response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res. 2018;24:5841\u20139.","journal-title":"Clin Cancer Res"},{"key":"1185_CR16","doi-asserted-by":"crossref","unstructured":"Goldstein DA, Gordon N, Davidescu M, et al. A phamacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non-small cell lung cancer. J Natl Cancer Inst. 2017;109(11):djx063.","DOI":"10.1093\/jnci\/djx063"},{"key":"1185_CR17","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1177\/10781552231212926","volume":"30","author":"L Chaitesipaseut","year":"2024","unstructured":"Chaitesipaseut L, Shah N, Truong TG, et al. Outcomes of weight-based vs. fixed dose of pembrolizumab among patients with non-small cell lung cancer. J Oncol Pharm Pract. 2024;30:1352\u20137.","journal-title":"J Oncol Pharm Pract"},{"key":"1185_CR18","doi-asserted-by":"crossref","unstructured":"Masip JR, Helissey C, Cozic N, et al. 106TiP pulse, a non-inferiority study of maintenance pembrolizumab at usual or low dose in non-squamous lung cancer. ESMO Open. 2024;9(Supplement 3):102685.","DOI":"10.1016\/j.esmoop.2024.102685"},{"key":"1185_CR19","doi-asserted-by":"publisher","first-page":"S806","DOI":"10.1016\/j.annonc.2024.08.1315","volume":"35","author":"M van den Heuvel","year":"2024","unstructured":"van den Heuvel M, van der Noort V, Ter Heine R. 1258MO Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: results of the pre-planned interim analysis of the NVALT-30 clinical trial. Ann Oncol. 2024;35:S806.","journal-title":"Ann Oncol"},{"key":"1185_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107950","volume":"196","author":"GF Grit","year":"2024","unstructured":"Grit GF, van Geffen E, Malmberg R, et al. Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: a nationwide retrospective cohort study with a non-inferiority primary objective. Lung Cancer. 2024;196:107950.","journal-title":"Lung Cancer"},{"key":"1185_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/ijc.33534","volume":"149","author":"JL Low","year":"2021","unstructured":"Low JL, Huang Y, Sooi K, et al. Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer. Int J Cancer. 2021;149:169\u201376.","journal-title":"Int J Cancer"},{"key":"1185_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/GO-24-00409","volume":"11","author":"C Hoyek","year":"2025","unstructured":"Hoyek C, Zheng-Lin B, Bauernfeind JJ, et al. Overcoming financial and access barriers in global cancer care with low-dose immunotherapy: a systematic review. JCO Glob Oncol. 2025;11:e2400409.","journal-title":"JCO Glob Oncol"},{"key":"1185_CR23","doi-asserted-by":"crossref","unstructured":"Chang KC, Shao SC, Chen HY, Chan YY, Fang YF. Comparative effectiveness and safety of standard-dose and low-dose pembrolizumab in patients with non-small-cell lung cancer: a multi-institutional cohort study in Taiwan. Cancers (Basel). 2022;14(5):1157.","DOI":"10.3390\/cancers14051157"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01185-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01185-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01185-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:10:23Z","timestamp":1764605423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01185-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1185"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01185-x","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ML, TF, and JAH are employees of MSD, and own stock in Merck & Co., Inc., Rahway, NJ, USA. AB reports grants or contracts from AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, MSD, Novartis, Onkure, and Pfizer and consulting fees from Alyssum, AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Menarini, MSD, Novartis, and Pfizer. AC reports grants or contracts from MSD and Pfizer; consulting fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, MSD, Novartis, Pfizer, Roche\/Genentech, Takeda, BeiGene, Summit, Therapeutics, Amgen, Janssen, Regeneron, and Sanofi; payment or honoraria for lectures presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Novartis, Pfizer, Roche, Pierre-Fabre, and PharmaMar; and support for attending meetings and\/or travel from Boehringer Ingelheim, MSD, Roche, Pfizer, and AstraZeneca. RD reports consulting fees from Roche, Pfizer, Gilead, Lilly, SOBI, Galderma, Sanofi, Novartis, and Bayer; payment or honoraria for lectures presentations, speakers bureaus, manuscript writing or educational events from MSD, Eisai, AstraZeneca, Roche, Pfizer, Gilead, Lilly, SOBI, Galderma, Sanofi, Novartis, and Bayer; and support for attending meetings and\/or travel from Bayer and Novartis. RSH reports grants or contracts from AstraZeneca, Eli Lilly and Company, Genentech\/Roche, and MSD; consulting fees from AstraZeneca, Amgen, ArriVent, Bristol Myers Squibb, Candel Therapeutics, Inc., Catalym, Checkpoint Therapeutics, Cybrexa Therapeutics, Eli Lilly and Company, Genentech, Gilead, I-Mab Biopharma, Immunocore, Janssen, Mediflix, MSD, NextCure, Novartis, Pfizer, Regeneron, and Roche; support for attending meetings and\/or travel from AstraZeneca, Genentech\/Roche, and MSD; participation on a Data Safety Monitoring Board or Advisory board for AstraZeneca, Candel Therapeutics, Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, I-Mab Biopharma, Immune-Onc Therapeutics, Inc., Immunocore, and Novartis; a leadership or fiduciary role in other board, society, committee, or advocacy group, paid or unpaid, for the American Association for Cancer Research, International Association for the Study of Lung Cancer, Society for Immunotherapy of Cancer, and Southwest Oncology Group Friends of Cancer Research; stock or stock options in Bolt Biotherapeutics, Checkpoint Therapeutics, and Immunocore Holdings Limited; and is a board member (nonexecutive\/independent) for Immunocore Holdings Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD) is committed to providing qualified scientific researchers access to anonymized data and clinical study reports from the company\u2019s clinical trials for the purpose of conducting legitimate scientific research. MSD is also obligated to protect the rights and privacy of trial participants and, as such, has a procedure in place for evaluating and fulfilling requests for sharing company clinical trial data with qualified external scientific researchers. The MSD data sharing website (available at:\n                      \n                      ) outlines the process and requirements for submitting a data request. Applications will be promptly assessed for completeness and policy compliance. Feasible requests will be reviewed by a committee of MSD participant matter experts to assess the scientific validity of the request and the qualifications of the requestors. In line with data privacy legislation, submitters of approved requests must enter into a standard data-sharing agreement with MSD before data access is granted. Data will be made available for request after product approval in the US and EU or after product development is discontinued. There are circumstances that may prevent MSD from sharing requested data, including country- or region-specific regulations. If the request is declined, it will be communicated to the investigator. Access to genetic or exploratory biomarker data requires a detailed, hypothesis-driven statistical analysis plan that is collaboratively developed by the requestor and MSD participant matter experts; after approval of the statistical analysis plan and execution of a data-sharing agreement, MSD will either perform the proposed analyses and share the results with the requestor or will construct biomarker covariates and add them to a file with clinical data that is uploaded to an analysis portal so that the requestor can perform the proposed analyses.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ML contributed to conceptualization, investigation, methodology, project administration, supervision, visualization, writing\u2014original draft, and writing\u2014 review and editing. AB contributed to conceptualization, writing\u2014original draft, and writing\u2014 review and editing. AC contributed to resources, validation, writing\u2014original draft, and writing\u2014 review and editing. RD contributed to conceptualization, validation, and writing\u2014review and editing. TF contributed to conceptualization, methodology, and writing\u2014review and editing. JAH contributed to conceptualization, formal analysis, investigation, methodology, supervision, writing\u2014original draft, and writing\u2014 review and editing. RH contributed to conceptualization, formal analysis, writing\u2014original draft, and writing\u2014 review and editing.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}